[Condylomata acuminata and associated infections--possibilities for therapy with interferon].
Recombinant alpha-Interferon can be used in primary therapy of condylomata acuminata. In our patients we found a response rate of 53%. Besides use in primary therapy the significant low rate of recurrences is important, thus offering the possibility of adjuvant interferon therapy after primary surgical treatment, where laser-vaporisation is best applied. Possible applications for primary and secondary treatment are shown. The rate of additional infections is of great importance; besides common agents for vaginal infections we found an elevated rate of HPV 16/18 with 47%.
Zwiorek
L
L
Zentrum für Frauenheikunde und Geburtshilfe, Philipps-Universität, Marburg.
Schmidt-Rhode
P
P
Goerke
K
K
Schulz
K D
KD
D000287:Administration, Topical; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000601:surgery / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D016899:Interferon-beta / Q000008:administration & dosage*; D053685:Laser Therapy; D027383:Papillomaviridae / Q000187:drug effects*; D011994:Recombinant Proteins; D014412:Tumor Virus Infections / Q000601:surgery / Q000628:therapy*; D014625:Vaginal Neoplasms / Q000601:surgery / Q000628:therapy*; D014846:Vulvar Neoplasms / Q000601:surgery / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016899:Interferon-beta
Condylomata acuminata und assoziierte Infektionen--Möglichkeiten der Therapie mit Interferon.